Properties
What is it?
International Nonproprietary Name - enoxaparin sodium Trade name of the preparation: Hemoxiparin International Nonproprietary Name: Enoxaparin sodium salt Dosage form: Solution for injection Composition: Salt 3000 anti-Xa ME (30 mg); excipients: water for injection - up to 0.3 ml. 1 syringe (0.4 ml) contains as active substance enoxaparin sodium salt 4000 anti-Xa ME (40 mg); excipients: water for injection - up to 0.4 ml. 1 syringe (0.5 ml) contains as active substance enoxaparin sodium salt 6000 anti-Xa ME (60 mg); excipients: water for injection - up to 0.6 ml. 1 syringe (0.7 ml) contains as active substance enoxaparin sodium salt 8000 anti-Xa ME (80 mg); excipients: water for injection - up to 0.8 ml. 1 syringe (1.0 ml) contains as active substance enoxaparin sodium Pharmacological properties Description Enoxaparin sodium salt - low molecular weight heparin. Average molecular weight approximately 4500 Daltons: less than 2000 Daltons - < 20%, from 2000 to 8000 Daltons - > 68%, more than 8000 Daltons - < 18%. Enoxaparin sodium salt is obtained by alkaline hydrolysis of heparin benzyl ether, isolated from the mucous membrane of the pig's small intestine. Its structure is characterized by a non-reducing fragment of 2-O-sulfo-4-enpyranuronic acid and a reducing fragment of 2-N,6-O-disulfo-D-glucopyranoside. The structure of enoxaparin sodium salt contains approximately 20% (in the range of 15% to 25%) of the 1,6-anhydro-derived fragment in the reducing fragment of the polysaccharide chain. Indications for use - Prevention of venous thrombosis and embolism, especially during orthopedic and general surgical operations; - Prevention of venous thrombosis and embolism in bedridden patients with acute therapeutic diseases (acute heart failure and decompensated chronic heart failure (NYHA class III or IV), associated with acute respiratory failure; acute infectious diseases, acute stages of rheumatic diseases combined with one of the risk factors for venous thrombosis (see "Special Indications"); - Treatment of pulmonary artery thromboembolism or deep vein thrombosis without it; - Treatment of unstable angina and non-Q-wave myocardial infarction in combination with aspirin; - Prevention of thrombosis during hemodialysis in an extracorporeal circulation system (usually for a session duration not exceeding 4 hours); - Treatment of acute myocardial infarction with ST-segment elevation in patients undergoing drug therapy or subsequent percutaneous coronary intervention. Use during pregnancy and lactation Currently available clinical data are insufficient to determine the possible teratogenic or fetotoxic effects of enoxaparin sodium when prescribed prophylactically during pregnancy. Hemoxiparin should not be used during pregnancy except when the potential benefit to the mother outweighs the potential risk to the fetus. Do not undergo spinal or epidural anesthesia during treatment with the preparation. If epidural anesthesia is planned, preventive treatment with enoxaparin sodium should be discontinued, if possible, at least 12 hours before anesthesia.